Brian Kirby

Brian Kirby

Auto-generated profile, based on publicly available information

Brian Kirby

St. Vincent's University Hospital, Elm Park Dublin Ireland

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2023 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
JKJames G Krueger
James G Krueger
JFJohn Frew
John Frew
GJGregor B E Jemec
Gregor B E Jemec
AKAlexa B Kimball
Alexa B Kimball
BKBrian Kirby
Brian Kirby
KWKerstin Wolk
Kerstin Wolk
Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic disabling and debilitating inflammatory disease with a high unmet medical need. The prevalence of HS reported in most studies is 1–2%, although it is likely to be under-reported and estimates vary globally owing to variance in data collection methods, ethnicity, geographical location and under-diagnosis. HS is characterized by persistent, painful cutaneous nodules, abscesses and draining tunnels commonly affecting the axillary, anogenital, inguinal and perianal/gluteal areas. Over time, chronic uncontrolled inflammation results in irreversible tissue destruction and scarring. Although the pathophysiology of HS has not been fully elucidated, the tumour necrosis factor (TNF)-α and interleukin (IL)-17 pathways have an important role, involving multiple cytokines. Currently, treatment options include topical medications; systemic therapies, including repeated and/or rotational courses of systemic antibiotics, retinoids and hormonal therapies; and various surgical procedures. The anti-TNF-α antibody adalimumab is currently the only biologic approved by both the US Food and Drug Administration and the European Medicines Agency for HS; however, its efficacy varies, with a clinical response reported in approximately 50% of patients in phase III trials. HS is a rapidly evolving field of discovery, with a diverse range of agents with distinct mechanisms of action currently being explored in clinical trials. Several other promising therapeutic targets have recently emerged, and agents targeting the IL-17 and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways are the most advanced in ongoing or completed phase III clinical trials. Alongside limited therapeutic options, significant challenges remain in terms of diagnosis and disease management, with a need for better treatment outcomes. Other unmet needs include significant diagnostic delays, thus missing the therapeutic ‘window of opportunity’; the lack of standardized outcome measures in clinical trials; and the lack of established, well-defined disease phenotypes and biomarkers.

12 November 2007 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
BKB. Kirby
B. Kirby
HRH.L. Richards
H.L. Richards
DMD.L. Mason
D.L. Mason
DFD.G. Fortune
D.G. Fortune
CMC.J. Main
C.J. Main
Chris EM GriffithsChris EM Griffiths
Chris EM Griffiths

25 March 2019 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
LJLorraine Jennings
Lorraine Jennings
RHRoisin Hambly
Roisin Hambly
RHRosalind Hughes
Rosalind Hughes
BMBlaithin Moriarty
Blaithin Moriarty
BKBrian Kirby
Brian Kirby
Background: Hidradenitis Suppurativa (HS) is a chronic debilitating inflammatory disease, associated with metabolic syndrome, obesity and insulin resistance. Metformin, an oral hypoglycaemic agent, may play an important role in delaying or preventing the onset of diabetes and metabolic syndrome. Metformin has been reported as having efficacy in HS. It may have a role in the treatment of HS and its associated co-morbidities. Objective: To evaluate metformin use, response and tolerability in a HS population. Methods: A retrospective chart review of patients attending a specialist Dermatology HS clinic over 12-months. All patients treated with metformin were included. Results: 53 HS patients received metformin; 85% female; mean age was 37years and mean weight was 102kg. The mean duration of metformin was 11.3months and mean dose was 1.5g/day. The six and 12-month drug survival were 61% and 39% respectively. Metformin was well tolerated. Gastrointestinal side-effects were experienced by 11%. Subjective clinical response was seen in 68%(n = 36) with 19%(7/36) of these having quiescent disease with metformin monotherapy. 25% had no improvement. Insulin resistance was seen in 75%. Its presence did not predict clinical response to metformin. Conclusion: Metformin is an effective, well tolerated and inexpensive treatment, that represents a viable treatment option for HS. Key message: Metformin is an effective, well tolerated and inexpensive treatment in the management of HS

1 March 2007 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
RHR. Hughes
R. Hughes
DWD. Ward
D. Ward
ATA. M. Tobin
A. M. Tobin
KKK. Keegan
K. Keegan
BKB. Kirby
B. Kirby

30 August 2023 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
APAndreea Petrasca
Andreea Petrasca
RHRoisin Hambly
Roisin Hambly
NKNiamh Kearney
Niamh Kearney
CSConor M Smith
Conor M Smith
EPEmily K Pender
Emily K Pender
JFJean M Fletcher
Jean M Fletcher
Background: Targeting immunometabolism has shown promise in treating autoimmune and inflammatory conditions. Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease involving painful lesions in apocrine gland-bearing skin. Therapeutic options for HS are limited and often ineffective; thus, there is a pressing need for improved treatments. To date, metabolic dysregulation has not been investigated in HS. As HS is highly inflammatory, we hypothesized that energy metabolism is dysregulated in these patients. Metformin, an antidiabetic drug, which is known to impact on cellular metabolic and signalling pathways, has been shown to have anti-inflammatory effects in cancer and arthritis. While metformin is not licensed for use in HS, patients with HS taking metformin show improved clinical symptoms. Objective: To assess the effect and mechanism of action of metformin in HS. Methods: To assess the effect of metformin in vivo, we compared the immune and metabolic profiles of peripheral blood mononuclear cells (PBMCs) of patients with HS taking metformin vs. those not taking metformin. To examine the effect of metformin treatment ex vivo, we employed a skin explant model on skin biopsies from patients with HS not taking metformin, which we cultured with metformin overnight. We used enzyme-linked immunosorbent assays, multiplex cytokine assays and quantitative real-time polymerase chain reaction (RT-PCR) to measure inflammatory markers, and Seahorse flux technology and quantitative RT-PCR to assess glucose metabolism. Results: We showed that metabolic pathways are dysregulated in the PBMCs of patients with HS vs. healthy individuals. In metformin-treated patients, these metabolic pathways were restored and their PBMCs had reduced inflammatory markers following long-term metformin treatment. In the skin explant model, we found that overnight culture with metformin reduced inflammatory cytokines and chemokines and glycolytic genes in lesions and tracts of patients with HS. Using in vitro assays, we found that metformin may induce these changes via the NLR family pyrin domain containing 3 (NLRP3) inflammasome and the AMP-activated protein kinase (AMPK)–mammalian target of rapamycin (mTOR) pathway, which is linked to glycolysis and protein synthesis. Conclusions: Our study provides insight into the mechanisms of action of metformin in HS. The anti-inflammatory effects of metformin support its use as a therapeutic agent in HS, while its effects on immunometabolism suggest that targeting metabolism is a promising therapeutic option in inflammatory diseases, including HS.

1 August 2002 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
BKBrian Kirbya
Brian Kirbya
COCaroline M. Owena
Caroline M. Owena
RBRobert W. Blewittb
Robert W. Blewittb
VYVictoriz M. Yatesa
Victoriz M. Yatesa